Maxim Pharmaceuticals Reports Fiscal 2004 Financial Results
13 déc. 2004 03h12 HE
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, Dec. 13, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE:MAXM) today reported financial results for the fourth quarter and the year ended September...
Myriad Genetics Files IND For Drug Candidate From Compound Family Licensed From Maxim Pharmaceuiticals
09 déc. 2004 07h15 HE
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, Dec. 9, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE:MAXM) today reported that Myriad Genetics, Inc., filed an Investigational New Drug (IND)...
Maxim Pharmaceuticals Reports Data from its Phase 3 Trial of Ceplene in Acute Myeloid Leukemia Patients at American Society of Hematology Annual Meeting
06 déc. 2004 14h54 HE
|
Maxim Pharmaceuticals
SAN DIEGO, Dec. 6, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today additional data from its randomized and controlled Phase 3 trial (MP-MA-0201) investigating...
Maxim's Senior Director of Regulatory Affairs and Drug Safety Resigns
06 déc. 2004 14h29 HE
|
Maxim Pharmaceuticals
SAN DIEGO, Dec. 6, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today that Richard Lowenthal, Senior Director of Regulatory Affairs and Drug Safety at Maxim, has...
Maxim Pharmaceuticals to Host Conference Call
03 déc. 2004 00h58 HE
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden, and SAN DIEGO, Dec. 3, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced it will hold a conference call on Tuesday, December 7, 2004 at 10:00 a.m....
Maxim Pharmaceuticals Announces Publication of Two Manuscripts Describing Pre-Clinical Anticancer Activity in Novel Class of Microtubule Inhibitors
01 déc. 2004 14h21 HE
|
Maxim Pharmaceuticals
SAN DIEGO, Dec. 1, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today the publication of two manuscripts in the Journal of Molecular Cancer Therapeutics (Mol Cancer...
Maxim Pharmaceuticals to Close Treatment Protocol and Withdraw NDA for Advanced Malignant Melanoma
01 nov. 2004 03h08 HE
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, Nov. 1, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today that based upon the negative outcome of it's confirmatory Phase 3 clinical...
Maxim Pharmaceuticals to Present at Rodman & Renshaw Conference
22 oct. 2004 03h10 HE
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden, Oct. 22, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that it will present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference...
Maxim Pharmaceuticals Appoints John F. Bedard To Board Of Directors
05 oct. 2004 03h04 HE
|
Maxim Pharmaceuticals
SAN DIEGO and STOCKHOLM, Sweden, Oct. 5, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today that John F. Bedard, 55, was appointed to the Company's board of directors....
Maxim Pharmaceuticals Presents Preclinical Results of Novel Cancer Compound Discovered by Its Research Team at The AACR-EORTC
01 oct. 2004 02h11 HE
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, Oct. 1, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) reported earlier this week at the AACR-EORTC-NCI International Conference "Molecular...